Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A

Saqib Masroor, Silviu Itescu, John H. Artrip, Oktavijan P. Minanov, Roland Buelow, Robert E. Michler

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. The synthetic peptide corresponding to residues 75-84 of the human major histocompatibility complex class I molecule HLA-B7 (Allotrap 07) has been shown to inhibit differentiation of cytotoxic T lymphocyte precursors. Subsequent treatment of LEW-1A rats with this peptide was associated with a reduction in the level of cytotoxic activity directed to donor alloantigens. This study was undertaken to investigate the effect of Allotrap 07 on rodent heart allograft survival in LEW-1A recipients. Methods. Heart allografts from Lewis rats were heterotopically transplanted into the infrarenal abdominal aorta of ACI recipients. The treatment groups consisted of different regimens of short-term intravenous Allotrap 07 and oral cyclosporin A. All grafts were palpated daily, with rejection defined as the cessation of palpable contractions. Results. Cardiac allografts transplanted from Lewis to ACI rats survived indefinitely after administration of intravenous Allotrap 07 and oral cyclosporin A. Tolerance induction was donor-specific because third-party Brown-Norway, but not Lewis, grafts were rapidly rejected after implantation into ACI recipients. Conclusions. Because donor-specific tolerance persisted long after cessation of peptide administration and did not occur when cyclosporin A was omitted from the immunosuppressive regimen, the mechanism may involve induction of clonal anergy.

Original languageEnglish (US)
Pages (from-to)144-148
Number of pages5
JournalAnnals of Thoracic Surgery
Volume65
Issue number1
DOIs
StatePublished - Jan 1998
Externally publishedYes

Fingerprint

Cyclosporine
Rodentia
Allografts
Peptides
Clonal Anergy
Inbred ACI Rats
HLA-B7 Antigen
Transplants
Isoantigens
Abdominal Aorta
Cytotoxic T-Lymphocytes
Norway
Immunosuppressive Agents
Major Histocompatibility Complex
Intravenous Administration
peptide A
allotrap
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A. / Masroor, Saqib; Itescu, Silviu; Artrip, John H.; Minanov, Oktavijan P.; Buelow, Roland; Michler, Robert E.

In: Annals of Thoracic Surgery, Vol. 65, No. 1, 01.1998, p. 144-148.

Research output: Contribution to journalArticle

Masroor, Saqib ; Itescu, Silviu ; Artrip, John H. ; Minanov, Oktavijan P. ; Buelow, Roland ; Michler, Robert E. / Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A. In: Annals of Thoracic Surgery. 1998 ; Vol. 65, No. 1. pp. 144-148.
@article{0f1244eb23d440f1a5cf332076ae5e20,
title = "Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A",
abstract = "Background. The synthetic peptide corresponding to residues 75-84 of the human major histocompatibility complex class I molecule HLA-B7 (Allotrap 07) has been shown to inhibit differentiation of cytotoxic T lymphocyte precursors. Subsequent treatment of LEW-1A rats with this peptide was associated with a reduction in the level of cytotoxic activity directed to donor alloantigens. This study was undertaken to investigate the effect of Allotrap 07 on rodent heart allograft survival in LEW-1A recipients. Methods. Heart allografts from Lewis rats were heterotopically transplanted into the infrarenal abdominal aorta of ACI recipients. The treatment groups consisted of different regimens of short-term intravenous Allotrap 07 and oral cyclosporin A. All grafts were palpated daily, with rejection defined as the cessation of palpable contractions. Results. Cardiac allografts transplanted from Lewis to ACI rats survived indefinitely after administration of intravenous Allotrap 07 and oral cyclosporin A. Tolerance induction was donor-specific because third-party Brown-Norway, but not Lewis, grafts were rapidly rejected after implantation into ACI recipients. Conclusions. Because donor-specific tolerance persisted long after cessation of peptide administration and did not occur when cyclosporin A was omitted from the immunosuppressive regimen, the mechanism may involve induction of clonal anergy.",
author = "Saqib Masroor and Silviu Itescu and Artrip, {John H.} and Minanov, {Oktavijan P.} and Roland Buelow and Michler, {Robert E.}",
year = "1998",
month = "1",
doi = "10.1016/S0003-4975(97)01258-7",
language = "English (US)",
volume = "65",
pages = "144--148",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Induction of tolerance in rodent cardiac allotransplantation using an MHC class I-derived peptide and cyclosporin A

AU - Masroor, Saqib

AU - Itescu, Silviu

AU - Artrip, John H.

AU - Minanov, Oktavijan P.

AU - Buelow, Roland

AU - Michler, Robert E.

PY - 1998/1

Y1 - 1998/1

N2 - Background. The synthetic peptide corresponding to residues 75-84 of the human major histocompatibility complex class I molecule HLA-B7 (Allotrap 07) has been shown to inhibit differentiation of cytotoxic T lymphocyte precursors. Subsequent treatment of LEW-1A rats with this peptide was associated with a reduction in the level of cytotoxic activity directed to donor alloantigens. This study was undertaken to investigate the effect of Allotrap 07 on rodent heart allograft survival in LEW-1A recipients. Methods. Heart allografts from Lewis rats were heterotopically transplanted into the infrarenal abdominal aorta of ACI recipients. The treatment groups consisted of different regimens of short-term intravenous Allotrap 07 and oral cyclosporin A. All grafts were palpated daily, with rejection defined as the cessation of palpable contractions. Results. Cardiac allografts transplanted from Lewis to ACI rats survived indefinitely after administration of intravenous Allotrap 07 and oral cyclosporin A. Tolerance induction was donor-specific because third-party Brown-Norway, but not Lewis, grafts were rapidly rejected after implantation into ACI recipients. Conclusions. Because donor-specific tolerance persisted long after cessation of peptide administration and did not occur when cyclosporin A was omitted from the immunosuppressive regimen, the mechanism may involve induction of clonal anergy.

AB - Background. The synthetic peptide corresponding to residues 75-84 of the human major histocompatibility complex class I molecule HLA-B7 (Allotrap 07) has been shown to inhibit differentiation of cytotoxic T lymphocyte precursors. Subsequent treatment of LEW-1A rats with this peptide was associated with a reduction in the level of cytotoxic activity directed to donor alloantigens. This study was undertaken to investigate the effect of Allotrap 07 on rodent heart allograft survival in LEW-1A recipients. Methods. Heart allografts from Lewis rats were heterotopically transplanted into the infrarenal abdominal aorta of ACI recipients. The treatment groups consisted of different regimens of short-term intravenous Allotrap 07 and oral cyclosporin A. All grafts were palpated daily, with rejection defined as the cessation of palpable contractions. Results. Cardiac allografts transplanted from Lewis to ACI rats survived indefinitely after administration of intravenous Allotrap 07 and oral cyclosporin A. Tolerance induction was donor-specific because third-party Brown-Norway, but not Lewis, grafts were rapidly rejected after implantation into ACI recipients. Conclusions. Because donor-specific tolerance persisted long after cessation of peptide administration and did not occur when cyclosporin A was omitted from the immunosuppressive regimen, the mechanism may involve induction of clonal anergy.

UR - http://www.scopus.com/inward/record.url?scp=0031907870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031907870&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(97)01258-7

DO - 10.1016/S0003-4975(97)01258-7

M3 - Article

VL - 65

SP - 144

EP - 148

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -